Canada Pension Plan Investment Board Buys Shares of 62,700 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Canada Pension Plan Investment Board purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 62,700 shares of the company's stock, valued at approximately $292,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI increased its stake in shares of GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after buying an additional 2,151 shares during the last quarter. Gagnon Securities LLC grew its position in GoodRx by 9.9% in the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock worth $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank grew its position in GoodRx by 4.1% in the fourth quarter. Swiss National Bank now owns 161,400 shares of the company's stock worth $751,000 after buying an additional 6,400 shares during the last quarter. Fortem Financial Group LLC grew its position in GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company's stock worth $554,000 after buying an additional 7,996 shares during the last quarter. Finally, RPO LLC acquired a new position in GoodRx in the fourth quarter worth approximately $52,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several recent research reports. Wells Fargo & Company decreased their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday. Citigroup decreased their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research note on Friday, January 10th. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Finally, Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, GoodRx presently has an average rating of "Moderate Buy" and an average price target of $7.84.

GoodRx Stock Performance

GDRX traded up $0.03 during midday trading on Tuesday, reaching $4.66. The company's stock had a trading volume of 448,983 shares, compared to its average volume of 1,375,401. The stock has a market cap of $1.79 billion, a P/E ratio of -155.33, a PEG ratio of 2.46 and a beta of 1.25. The company has a fifty day simple moving average of $4.57 and a 200 day simple moving average of $4.87. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a twelve month low of $3.82 and a twelve month high of $9.26.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.